Evidence map›Paper›PMID 29706565›Full record

ArticleCell metabolism2018

Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis.

Pengcheng Bu, Kai-Yuan Chen, Kun Xiang, Christelle Johnson, Scott B Crown, Nikolai Rakhilin, Yiwei Ai, Lihua Wang, Rui Xi, Inna Astapova and 11 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers.

0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed
21.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

182 citing papers in PubMed, 355 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. ChREBP-β Exacerbates Renal Tubular Disorders Caused by Fructose via ATF4.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. The moonlighting functions of glycolytic enzymes in tumorigenesis.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

122 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Pengcheng BuKey Laboratory of RNA Biology, Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA. Electronic address: bupc@ibp.ac.cn.
Kai-Yuan ChenDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Kun XiangDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Christelle JohnsonDepartment of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA; School of Electrical and Computer Engineering, Cornell University, Ithaca, NY 14853, USA.
Scott B CrownMolecular Physiology Institute, Duke University, Durham, NC 27701, USA.
Nikolai RakhilinDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA; School of Electrical and Computer Engineering, Cornell University, Ithaca, NY 14853, USA.
Yiwei AiDepartment of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.
Lihua WangDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Rui XiDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Inna AstapovaMolecular Physiology Institute, Duke University, Durham, NC 27701, USA; Department of Medicine, Duke University, Durham, NC 27701, USA.
Yan HanDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Jiahe LiDepartment of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.
Bradley B BarthDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Min LuDivision of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Ziyang GaoDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Robert MinesDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Liwen ZhangKey Laboratory of RNA Biology, Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Mark HermanMolecular Physiology Institute, Duke University, Durham, NC 27701, USA; Department of Medicine, Duke University, Durham, NC 27701, USA.
David HsuDepartment of Medicine, Duke University, Durham, NC 27701, USA; Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Guo-Fang ZhangMolecular Physiology Institute, Duke University, Durham, NC 27701, USA; Department of Medicine, Duke University, Durham, NC 27701, USA.
Xiling ShenDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA. Electronic address: xs37@duke.edu.
Duke University · USCornell University · USChinese Academy of Sciences · CNDuke Medical Center · US

Funding

MULTIDISCIPLINARY HEART &VASCULAR DISEASEST32HL007101 · NHLBI · DUKE UNIVERSITY · PI FREEDMAN, NEIL J. · 1985 to 2020
$9.8M
Robust Control of the Stem Cell NicheR35GM122465 · NIGMS · TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION · PI Xiling Shen · 2017 to 2026
$5.6M
An organotypic model recapitulating colon cancer microenvironment and metastasisU01CA214300 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HUANG, EMINA HUI-NA, SHEN, XILING · 2017 to 2021
$3.1M
Metabolic Reprogramming of Colon Cancer Liver MetastasisR21CA201963 · NCI · DUKE UNIVERSITY · PI LOCASALE, JASON W., SHEN, XILING · 2016 to 2017
$380k
NCI NIH HHS R21 CA201963NCI NIH HHS U01 CA214300NHLBI NIH HHS T32 HL007101NIGMS NIH HHS R35 GM122465
6 · The paper itself

Abstract

Cancer metastasis accounts for the majority of cancer-related deaths and remains a clinical challenge. Metastatic cancer cells generally resemble cells of the primary cancer, but they may be influenced by the milieu of the organs they colonize. Here, we show that colorectal cancer cells undergo metabolic reprogramming after they metastasize and colonize the liver, a key metabolic organ. In particular, via GATA6, metastatic cells in the liver upregulate the enzyme aldolase B (ALDOB), which enhances fructose metabolism and provides fuel for major pathways of central carbon metabolism during tumor cell proliferation. Targeting ALDOB or reducing dietary fructose significantly reduces liver metastatic growth but has little effect on the primary tumor. Our findings suggest that metastatic cells can take advantage of reprogrammed metabolism in their new microenvironment, especially in a metabolically active organ such as the liver. Manipulation of involved pathways may affect the course of metastatic growth.

Indexed as

Tumor MicroenvironmentAnimalsColorectal NeoplasmsFructoseFructose-Bisphosphate AldolaseHCT116 CellsHumansLiver NeoplasmsMiceMice, Inbred BALB CMice, Inbred NODNeoplasm MetastasisFructoseFructose-Bisphosphate AldolaseALDOBAldolase Bcolon cancercolorectal cancerfructoseGATA6livermetabolic reprogrammingmetabolismmetastasis

Identifiers

PMID29706565
PMCPMC5990465
OpenAlexW2802491677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.